PSA screening likely cuts prostate cancer deaths slightly; the overall survival effect is uncertain

Design

Cochrane systematic review and meta-analysis of randomised trials

Population

789,086 men without prostate cancer in six trials

Primary outcome

Prostate cancer-specific and all-cause mortality

Effect

Cancer-specific RR 0.87 (95% CI 0.80 to 0.95); all-cause RR 0.99 (0.97 to 1.00)

This abridged Cochrane review updates the 2013 version, searching to November 2025. It included six randomised trials of screening versus no screening (789,086 men, follow-up 3 to 23 years): five tested PSA alone and one, ProScreen, tested PSA with a kallikrein panel and MRI.

Based mainly on the lower-risk-of-bias ERSPC trial, screening likely reduces prostate cancer-specific mortality (RR 0.87, 95% CI 0.80 to 0.95; moderate certainty), which corresponds to about two fewer deaths per 1000 men. Across four trials, screening may slightly reduce all-cause mortality (RR 0.99, 0.97 to 1.00; low certainty), about five fewer deaths per 1000, with an interval that includes no effect. Adverse events and quality of life showed little difference, though the review measured harms narrowly. In ProScreen, the newer approach increased detection; mortality results are not yet available.

The benefit is real but small, and its weight depends on what difference a man considers worthwhile. Overdiagnosis and treatment side effects remain the main harms and are not fully captured here. This supports offering informed, shared decisions to men in the age groups covered by guidelines rather than either routine population screening or refusal. India has no national prostate screening programme, so the conversation usually happens opportunistically in clinic.

• Offer men in guideline age groups an informed discussion about PSA screening rather than testing by default.
• Explain the benefit in absolute terms: about two fewer prostate cancer deaths per 1000 men screened.
• Explain the harms: false positives, biopsy complications, overdiagnosis and treatment side effects.
• Use MRI before biopsy where available to reduce unnecessary biopsies and overdiagnosis.
• Record the discussion and the man's decision.

Why it matters

It gives a clear, current number to use in the screening conversation that most men raise in clinic.

Don't overread it

The review does not show an overall survival benefit, and it captures the harms of overdiagnosis only partly.

The statistics, in plain English

An RR of 0.87 means about 13% fewer prostate cancer deaths, but because these deaths are uncommon, the absolute gain is about two per 1000 men. The all-cause interval touches 1.00, so a true overall survival benefit cannot be confirmed. The review notes conclusions depend heavily on what threshold of benefit is considered meaningful.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.